SETD2 and nonpapillary renal cell carcinoma: Increased hypermethylation was associated with higher-stage disease in ccRCC, PRCC (with or without CIMP), and ChRCC (all p < 0.0001) and was associated with SETD2 mutation in ccRCC (p < 0.0001), either PBRM1 mutation or SETD2 mutation in type 2 PRCC (p = 0.0053, p = 0.0270, respectively), and TP53 mutation in ChRCC (p = 0.0119) (Figure S3B).